MSD (Merck Sharp & Dohme)
Research-intensive biopharmaceutical company focused on discovery, development and global delivery of medicines and vaccines across multiple therapeutic areas. Operates global R&D and manufacturing capabilities, runs large clinical trial programs, pursues collaborations and licensing, and maintains enterprise programs for sustainability, supplier engagement and impact investing.
Industries
Nr. of Employees
Very Large (1000+)
Products
Medicines and vaccines across therapeutic areas
Commercial medicines and vaccines developed for oncology, infectious diseases, cardiovascular disease, immunology, neuroscience, ophthalmology and other areas; distributed globally through clinical and commercial channels.
Multivitamin (with
Veterinary multivitamin formulation containing retinyl propionate, tocopheryl acetate, and colecalciferol in a liquid amber form.
Multivitamin (with Starch) Formulation
Multivitamin formulation with starch used as a veterinary product.
Bravecto
1-month chewable tablets containing 560 mg fluralaner for very large dogs.
BRAVECTO 112.5 MG FLURALANER CHEWABLE TABLETS FOR VERY SMALL DOGS
Chewable tablets containing 112.5 mg fluralaner for very small dogs.
Fluralaner / Moxidectin Liquid Formulation
A veterinary liquid formulation containing fluralaner and moxidectin for use as a veterinary antiparasitic product.
Medicines and vaccines across therapeutic areas
Commercial medicines and vaccines developed for oncology, infectious diseases, cardiovascular disease, immunology, neuroscience, ophthalmology and other areas; distributed globally through clinical and commercial channels.
Multivitamin (with
Veterinary multivitamin formulation containing retinyl propionate, tocopheryl acetate, and colecalciferol in a liquid amber form.
Multivitamin (with Starch) Formulation
Multivitamin formulation with starch used as a veterinary product.
Bravecto
1-month chewable tablets containing 560 mg fluralaner for very large dogs.
BRAVECTO 112.5 MG FLURALANER CHEWABLE TABLETS FOR VERY SMALL DOGS
Chewable tablets containing 112.5 mg fluralaner for very small dogs.
Fluralaner / Moxidectin Liquid Formulation
A veterinary liquid formulation containing fluralaner and moxidectin for use as a veterinary antiparasitic product.
Services
End-to-end clinical trial services including protocol design, monitoring, patient recruitment, biostatistics and data management.
Enterprise manufacturing operations and partnerships for APIs, large‑ and small‑molecule production, packaging and clinical supply distribution.
Business development and licensing to enable external collaborations, in‑licensing and out‑licensing of assets and technologies.
Programs for supplier inclusion, small business development, environmental sustainability and procurement training/mentoring.
Impact investing into funds and companies to support health system infrastructure, diagnostics, digital solutions and other interventions that strengthen access to care in low‑ and middle‑income settings.
End-to-end clinical trial services including protocol design, monitoring, patient recruitment, biostatistics and data management.
Enterprise manufacturing operations and partnerships for APIs, large‑ and small‑molecule production, packaging and clinical supply distribution.
Business development and licensing to enable external collaborations, in‑licensing and out‑licensing of assets and technologies.
Programs for supplier inclusion, small business development, environmental sustainability and procurement training/mentoring.
Impact investing into funds and companies to support health system infrastructure, diagnostics, digital solutions and other interventions that strengthen access to care in low‑ and middle‑income settings.
Expertise Areas
- Clinical trial management
- Diversity and access planning in clinical research
- Vaccine and biologics development
- Oncology research and immunotherapy
Key Technologies
- Machine learning
- Artificial intelligence for research and diagnostics
- Blockchain for supply‑chain integrity
- Digital health and telehealth platforms
News & Updates
Corporate impact and sustainability report summarizing access, environmental and ethics programs.
Company founded in 1891 and established early research laboratories supporting long-term pharmaceutical research.
Approval of the first recombinant hepatitis B vaccine, marking an early recombinant biologics milestone.
Regulatory approval of an anti–PD-1 immunotherapy for cancer, representing a major advance in oncology development.
Regulatory approval of an Ebola Zaire vaccine to prevent disease caused by Zaire ebolavirus.
Recognitions for impact investing and social impact work, including Fast Company World Changing Ideas honoree (2024), Reuters Social Impact Award finalist (2023) and Fortune Change the World list (2020).
Corporate impact and sustainability report summarizing access, environmental and ethics programs.
Company founded in 1891 and established early research laboratories supporting long-term pharmaceutical research.
Approval of the first recombinant hepatitis B vaccine, marking an early recombinant biologics milestone.
Regulatory approval of an anti–PD-1 immunotherapy for cancer, representing a major advance in oncology development.
Regulatory approval of an Ebola Zaire vaccine to prevent disease caused by Zaire ebolavirus.
Recognitions for impact investing and social impact work, including Fast Company World Changing Ideas honoree (2024), Reuters Social Impact Award finalist (2023) and Fortune Change the World list (2020).